FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
These products strengthen poultry immunity, improve productivity, and support sustainable farming practices~
Medico Remedies receives order worth US$ 1,781,000
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
Marks first international filing for Evofem’s single-dose oral treatment
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Subscribe To Our Newsletter & Stay Updated